Business
Valeo Pharma Closes $11.5 Million Bought-Deal Public Offering, Including Full Exercise of the Over-Allotment Option
Valeo Pharma Closes $11.5 Million Bought-Deal Public Offering, Including Full Exercise of the Over-Allotment Option.
About this update from Valeo Pharma Inc.
[{"type":"text","content":"\n\n\n\nValeo Pharma Closes $11.5 Million Bought-Deal Public Offering, Including Full Exercise of the Over-Allotment Option\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n\n\n\n\n\n\nValeo Pharma Closes $11.5 Million Bought-Deal Public Offering, Including Full Exercise of the Over-Allotment Option\nCanada NewsWire\nMONTREAL, June 29, 2021\n\n\n\n/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES/\n MONTREAL, June 29, 2021 /CNW Telbec/ - Valeo Pharma Inc. (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) (\"Valeo\" or the \"Company\"), a Canadian pharmaceutical company, is pleased to announce the closing of its bought-deal public offering pursuant to which the Company issued 11,500,000 units of the Company (the \"Units\") at a price of $1.00 per Unit for gross proceeds to the Company of $11,500,000 (the \"Offering\"), including the full exercise of the over-allotment option. The Offering was led by Research Capital Corporation, as the lead underwriter and sole bookrunner, on behalf of a syndicate of underwriters, including Paradigm Capital Inc. and Desjardins Capital Markets.\n\n \n \n \n \n \n \n\n \nEach Unit consists of one class A share in the capital of the Company (a \"Share\") and one Share purchase warrant of the Company (a \"Warrant\"). Each Warrant entitles the holder thereof to purchase one Share at an exercise price of $1.25 for a period of 36 months following the closing of the Offering. \nThe net proceeds from the Offering will be used by the Company for the purposes described in the final short form prospectus of the Company dated June 22, 2021.\nThis press release is not an offer to sell or the solicitation of an offer to buy the securities in the United States or in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to qualification or registration under the securities laws of such jurisdiction. The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and such securities may not be...